RxDoctor Payments DataLook up a doctor →

Richard Lane, MD

Retina Specialist · San Antonio, TXNPI 1922086347

Payments from drug & device makers

$4,700,860in general payments, 2019–2025

Across 1,908 payments — averaging $2463.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$1.9M
  • Ocular Therapeutix, Inc.$836K
  • Bayer$672K
  • AstraZeneca$499K
  • Boehringer Ingelheim$275K
  • Genentech, Inc.$186K
  • plus $356K from 28 others
$11,840in research payments, 2019–2025

Across 9 payments — averaging $1315.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$10K
  • Regeneron$1K

What the payments were for

  • Travel & lodging$1,91311%
  • Food & beverage$3,68421%
  • Gifts$1691%
  • Ownership interest$4,98329%
  • Other$6,65238%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,700,860 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas

Medicare billing

Part B allowed, 2024
$6,666,215
Medicare patients
1,234
Services billed
59,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate188$7,553
Difluprednate45$4,479
Ketorolac Tromethamine46$2,126
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat75$1,019
Tobramycin101$503
Brimonidine Tartrate32$436
MoxifloxacinMoxifloxacin Hcl20$393
ErythromycinErythromycin Base17$182
Timolol Maleate15$109

Paid to pharmacies, not to this prescriber.

Other retina specialist in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →